Research & Development In Brief
This article was originally published in The Tan Sheet
Executive Summary
Fish oil may cut breast cancer risk: Use of fish oil supplements reduces the risk of breast cancer in a seven-year study of 35,016 women aged 50 to 76 years in the Vitamins and Lifestyle cohort. But the study in the July issue of Cancer Epidemiology, Biomarkers and Prevention points out the use of other "specialty" supplements taken for menopausal symptoms, such as black cohosh, dong quai, soy and St. John's wort, were not similarly associated with reduced breast cancer risk. Researchers from the Fred Hutchinson Cancer Research Center and the University of California also say fish oil use was associated with reduced risk of invasive ductal, but not lobular, carcinoma. They hypothesize fish oil's benefit may come from its anti-inflammatory properties. Despite the inverse association between some breast cancer risk and fish oil use, the researchers do not advocate promoting the substance for prevention because their work was a first prospective study and does not consider timing of exposure or dose. Future studies are necessary, they add
You may also be interested in...
S-P Brings New Laxative Class To OTC Market Under Braintree Licensing Deal
Schering-Plough will position Braintree Laboratories' MiraLAX laxative as an effective treatment for occasional constipation without "harsh" side effects linked to other OTC laxative products
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands